Molecular Diagnosis & Therapy

, Volume 17, Issue 1, pp 57–62


A Guide to Its Use in First-Line Treatment of Non-Small-Cell Lung Cancer with Epidermal Growth Factor-Activating Mutations
Adis Drug Clinical Q&A

DOI: 10.1007/s40291-013-0015-x

Cite this article as:
Lyseng-Williamson, K.A. Mol Diagn Ther (2013) 17: 57. doi:10.1007/s40291-013-0015-x


In the EU, the approved use of erlotinib (Tarceva®), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has recently been expanded to include first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in patients with EGFR-activating mutations. In randomized, open-label, phase III clinical trials, oral erlotinib reduced the risk of progression, improved response rates, and was well tolerated relative to standard platinum-based doublet chemotherapy in Caucasian and Asian populations with advanced NSCLC with EGFR-activating mutations.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations